Brittnie Cave
Nurse Practitioner · Weirton, WVNPI 1023524212
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,680 and has fallen 89.2% since, to $182 in 2025. Among nurse practitioner clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$318
- Johnson & Johnson$308
- Novo Nordisk$266
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$249
- Amgen$182
- Novartis$161
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,846100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $318 |
| Johnson & Johnson | 12 | $308 |
| Novo Nordisk | 10 | $266 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $249 |
| Amgen | 9 | $182 |
| Novartis | 11 | $161 |
| Ferring Pharmaceuticals Inc. | 1 | $159 |
| Boehringer Ingelheim | 10 | $146 |
| Bayer | 6 | $114 |
| Cvrx, Inc. | 6 | $99 |
| AbbVie | 4 | $92 |
| Merck | 5 | $79 |
| Melinta Therapeutics, LLC | 3 | $65 |
| Scpharmaceuticals Inc. | 1 | $64 |
| Pfizer | 4 | $63 |
| Lilly USA, LLC | 4 | $58 |
| Organogenesis Inc. | 2 | $52 |
| Mylan Specialty L.p. | 3 | $49 |
| Kerecis Limited | 1 | $38 |
| Amarin Pharma, Inc. | 2 | $35 |
| Boston Scientific | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| KCI USA, Inc. | 2 | $31 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $26 |
| Arbor Pharmaceuticals, Inc. | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 2 | $25 |
| Smith+Nephew | 1 | $24 |
| Exact Sciences | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,846 in reported general payments places this provider in the 90th percentile of 649 nurse practitioner providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 97 | $88,614 |
| OtezlaApremilast | 12 | $57,892 |
| JardianceEmpagliflozin | 37 | $41,592 |
| EliquisApixaban | 61 | $40,276 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $36,779 |
| JanuviaSitagliptin Phosphate | 35 | $33,872 |
| FarxigaDapagliflozin Propanediol | 41 | $32,094 |
| MounjaroTirzepatide | 29 | $30,243 |
| TrulicityDulaglutide | 24 | $25,028 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $23,062 |
| LinzessLinaclotide | 24 | $13,029 |
| XareltoRivaroxaban | 19 | $10,395 |
| MyrbetriqMirabegron | 21 | $9,350 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $7,818 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $266 | $88,61497 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $318 | $60,55795 claims |
| AmgenOtezla | $182 | $57,89212 claims |
| Lilly USA, LLCMounjaro, Trulicity | $58 | $55,27153 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $146 | $46,99448 claims |
| PfizerEliquis | $63 | $40,27661 claims |
| MerckJanuvia, Belsomra | $79 | $39,66648 claims |
| AbbVieLinzess | $92 | $13,02924 claims |
| Johnson & JohnsonXarelto | $308 | $10,39519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 649 nurse practitioner providers in West Virginia.
Other nurse practitioner in Weirton
- Kara SlivaWeirton$5K
- Leigh BrooksPrinceton$75K
- Destiny HowardBeckley$35K
- Rachael RigginsBeckley$19K
- Lacy HowardWheeling$18K
- Robin BlumeBeckley$18K
- Kellie VaughtBeckley$17K
- Lisa WalkerBeckley$17K
- Rachel BrillSouth Charleston$16K
- Kelly HughartSouth Charleston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.